报价延迟最少15分钟:2026/09/18 17:17 EDT
盘后时段
|
||||
|
5.9 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.9
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.67/0.83
|
|
企业价值
297.06M
|
| 资产负债 |
|
每股账面净值
3.86
|
| 现金流量 |
|
现金流量率
0.09
|
| 损益表 |
|
收益
94.02M
|
|
每股收益
1.03
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland. |
